FindTrial
Sign In

Efficacy and Safety of Apremilast in refractory uveitis

Efficacy and Safety of Apremilast in refractory uveitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030234
Enrollment
Unknown
Registered
2020-02-25
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory uveitis

Interventions

Case series:Apremilast

Sponsors

Zhongshan Ophthalmic center, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients had uveitis refractory to glucocorticoids and had previously received at least 1 conventional synthetic immunosuppressive drug

Exclusion criteria

Exclusion criteria: Malignancy or systemic infectious diseases, including hepatitis B or C infection or tuberculosis.

Design outcomes

Primary

MeasureTime frame
vision;anterior uveitis activity;Central thickness of macula;Fundus vessels leakage;—

Secondary

MeasureTime frame
Intraocular pressure;—

Countries

China

Contacts

Public ContactWenru Su

Zhongshan Eye Center of Sun Yat-Sen University

suwr3@mail.sysu.edu.cn+86 13570364296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026